Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login

Your RPS

New video explains the risks of valproate in female patients

The Royal Pharmaceutical Society has worked with the Medicines and Healthcare products Regulatory Agency (MHRA) and the Royal College of General Practitioners to produce a short video about the risks of valproate, a medicine prescribed for epilepsy and bipolar disorder. The video is aimed at GPs, pharmacists and other healthcare professionals and gives an overview of the latest MHRA guidance on discussing the medication with patients.

It follows an announcement by the European Medicines Agency (EMA) that it will host a public hearing during which patients can share their experiences of taking valproate. The hearing, which takes place at the EMA’s London office, forms part of a review by the EMA’s Pharmacovigilance Risk Assessment Committee (PRAC) on the risks and benefits of valproate to women and girls of childbearing age.

Valproate is associated with serious harm to foetal development. It can cause birth defects and developmental disorders, and should not be taken by women and girls unless no other medication is effective. In April 2017, the RPS released a Quick Reference Guide to dispensing valproate for girls and women.

The MHRA said all women and girls taking valproate should be informed of the risks as well as the benefits of the medication.

The new video accompanies a toolkit on the risks of valproate previously developed by the three health bodies. Both the video and the toolkit may be accessed on the MHRA website. The video is also available on YouTube.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2017.20203487

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
PJJ Static MPU
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • valproate vid aug 17

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.